Physician profile
David L Register
NPI 1427780154
$6,885.50
in general payments reported to CMS, 2019-2025
17 companies · $1,945 in 2025
The $1,945 reported for 2025 was more than what 92% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $235 · 2023: $1,716 · 2024: $2,990 · 2025: $1,945.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,419 · Education: $231.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,419.10 |
| Education | $231.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,342.39 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,121.18 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $909.57 | 2023-2025 | Austedo Xr, Austedo Xr, Austedo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $777.84 | 2022-2025 | Caplyta |
| Alkermes, INC. | $617.60 | 2023-2025 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $580.22 | 2023-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $508.12 | 2022-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $220.75 | 2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $178.45 | 2022-2025 | Trintellix |
| Lundbeck LLC | $173.25 | 2022-2024 | Rexulti |
| Almatica Pharma LLC | $165.38 | 2022-2025 | Loreev Xr, Gralise |
| Janssen Pharmaceuticals, INC | $97.19 | 2023-2024 | Spravato |
| Vanda Pharmaceuticals INC. | $59.34 | 2023 | Fanapt, Hetlioz |
| Idorsia Pharmaceuticals US INC | $51.59 | 2023-2024 | Quviviq |
| Corium, LLC | $46.91 | 2022-2023 | Azstarys |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $22.62 | 2023 | Dyanavel Xr |
| Indivior INC. | $13.10 | 2023 | Perseris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Register listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.